Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W5HK
|
|||
| Former ID |
DAP000006
|
|||
| Drug Name |
Sorafenib
|
|||
| Synonyms |
Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Approved | [1], [2] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0] | Phase 3 | [1], [3] | ||
| Myelodysplastic syndrome [ICD-11: 2A37] | Phase 2 | [1], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bayer AG; Onyx Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H16ClF3N4O3
|
|||
| Canonical SMILES |
CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
|
|||
| InChI |
1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
|
|||
| InChIKey |
MLDQJTXFUGDVEO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 284461-73-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
833589, 833590, 7886069, 9372814, 12015507, 14720365, 14834034, 30419984, 46505329, 46516901, 50069824, 50070560, 50071324, 50100118, 50112741, 53787819, 53799234, 56312334, 56312336, 56312338, 56312517, 56312519, 56312521, 56394953, 57399755, 68529952, 74382940, 75518900, 81092852, 85174603, 85285882, 85845166, 91148447, 92718861, 93581025, 96025209, 99443909, 103420820, 103904444, 104178872, 113461200, 117695450, 117871124, 124767621, 124893320, 124893321, 124893322, 124893323, 124893324, 125346960
|
|||
| ChEBI ID |
CHEBI:50924
|
|||
| ADReCS Drug ID | BADD_D02058 | |||
| SuperDrug ATC ID |
L01XE05
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711). | |||
| REF 2 | Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. | |||
| REF 3 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 4 | Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16. | |||
| REF 5 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.